Please login to the form below

Not currently logged in
Email:
Password:

dolutegravir

This page shows the latest dolutegravir news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

It combines ViiV’s own Tivicay (dolutegravir) the most widely prescribed integrase inhibitor worldwide, and J&J’s  Edurant (rilpivirine).

Latest news

More from news
Approximately 8 fully matching, plus 42 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Developing your patient-centric strategy

    The 2013 PatientView survey likely scored ViiV well on the product front too, as 2013 saw the company’ s HIV therapy Tivicay (dolutegravir) approved in the US and recommended for European

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics